Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Olon Opens New R&D Site In Milan

API Specialist Also Reveals Expansion Plan For Mahad Manufacturing Facility In India

Executive Summary

Italy’s Olon has opened its new R&D hub in Milan, shortly after announcing plans to expand a key manufacturing facility in India.

You may also be interested in...

Sandoz Takes Treble Honors At GGB Awards 2023

Sandoz has triumphed at the Global Generics & Biosimilars Awards 2023, taking home three prizes while Samsung Bioepis also walked away with multiple trophies at our prizegiving ceremony in Barcelona.

Olon Expands On Multiple Fronts

Italian API and CDMO specialist Olon is expanding its high-potency capabilities at a site in India, at the same time as unveiling plans to invest a further €30m in a domestic biotech hub.

Olon Invests In R&D Hub In Italy

Italy’s Olon has announced a €10m investment in a new R&D hub in Rodano, Milan, that the active pharmaceutical ingredient specialist says will help to consolidate its expertise and connect its worldwide network of 11 facilities.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts